Neuropsychiatric Immune-related Adverse Events Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma and Systemic Lupus Erythematosus-Reference-Cited by-同舟云学术

Neuropsychiatric Immune-related Adverse Events Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma and Systemic Lupus Erythematosus

Published:2020-02-15 Issue:4 Volume:59 Page:569-572
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Jono Misato¹,Kinehara Yuhei¹,Utsu Yoshihiko¹,Tamura Yoshiro¹,Koseto Masahiro¹,Murakami Teruaki¹,Uota Akifumi¹,Ninomiya Ryusuke¹,Komo Satoshi¹,Sumitani Satoru¹,Sato Bunzo¹,Kasayama Soji¹,Tachibana Isao¹

Affiliation:

1. Department of Medicine, Nippon Life Hospital, Japan

Publisher

Japanese Society of Internal Medicine

Subject

General Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/59/4/59_3782-19/_pdf

Reference20 articles.

1. 1. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373: 1627-1639, 2015.

2. 2. Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375: 1823-1833, 2016.

3. 3. Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389: 255-265, 2017.

4. 4. Gandhi L, Rodriguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 378: 2078-2092, 2018.

5. 5. Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med 379: 2040-2051, 2018.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Autoimmune Movement Disorders Complicating Treatment with Immune Checkpoint Inhibitors;Movement Disorders Clinical Practice;2024-02-23

2. Construction of a genomic instability-derived predictive prognostic signature for non-small cell lung cancer patients;Cancer Genetics;2023-11

3. Neurological Complications of Conventional and Novel Anticancer Treatments;Cancers;2022-12-10

4. Adverse cutaneous toxicities by PD-1/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance;Cutaneous and Ocular Toxicology;2022-01-02

5. Progressive multifocal leukoencephalopathy in systemic lupus erythematosus managed with pembrolizumab: A case report with literature review;Lupus;2021-07-29